Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Profound Medical ( (TSE:PRN) ).
Profound Medical Corp. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where management will present an update on the company’s business. This presentation is significant as it may enhance Profound’s visibility in the medical device industry and potentially bolster its market position. The conference serves as a platform for showcasing their advanced technologies like TULSA-PRO® and Sonalleve®, which could attract further investor interest and partnerships.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue. They are known for their TULSA-PRO® system, which offers an innovative treatment for prostate disease using real-time MRI and ultrasound technology, and Sonalleve®, a platform for treating uterine fibroids and bone metastases. The company’s technologies are approved across various global markets, including Health Canada and the FDA.
YTD Price Performance: -1.84%
Average Trading Volume: 9,792
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$336.9M
For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.
